CuResponse: Funding, Investors & Team (Sep 2026)
Curesponse is a medical company developing a three-dimensional tissue culture system for modeling cancer growth and drug response. The company's technology represents the next step in personalized cancer medicine, moving prediction capabilities beyond genomics and into the world of functional response on living patient cells. The platform preserves the cancer tissue architecture, including the vasculature and immune system, accurately reflecting the cancer growth found in the body. Curesponse’s cutting edge functional platform will match the correct drug to the patient's cancer, improving survival and saving unnecessary medical interventions. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type.
CuResponse has raised $6.0M across 1 funding round on record, the most recent an undisclosed round of $6.0M announced in Jun 2020.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CuResponse Company Profile and Key Stats
Latest funding round on record: Jun 2020.
CuResponse Funding Rounds
CuResponse Founders and Leadership Team
No contact details are on record for this team yet.
CuResponse Funding Compared to Other Biotechnology Startups
CuResponse's latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CuResponse in Biotechnology and Tel Aviv-yafo
Companies Similar to CuResponse
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
CuResponse Funding FAQs
What does CuResponse do?
Curesponse is a medical company developing a three-dimensional tissue culture system for modeling cancer growth and drug response. The company's technology represents the next step in personalized cancer medicine, moving prediction capabilities beyond genomics and into the world of functional response on living patient cells. The platform preserves the cancer tissue architecture, including the vasculature and immune system, accurately reflecting the cancer growth found in the body. Curesponse’s cutting edge functional platform will match the correct drug to the patient's cancer, improving survival and saving unnecessary medical interventions. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type.
How much funding has CuResponse raised?
CuResponse has raised $6.0M across 1 round on record. The most recent is an undisclosed round of $6.0M announced in Jun 2020.
When did CuResponse last raise funding?
CuResponse's most recent funding round on record is an undisclosed round of $6.0M, announced in Jun 2020.
Who is the CEO of CuResponse?
Guy Neev is listed as CEO at CuResponse.
Where is CuResponse headquartered?
CuResponse is based in Tel Aviv-yafo, Tel Aviv, Israel.
How many employees does CuResponse have?
CuResponse is in the 11-50 employee band.
How does CuResponse's funding compare to other Biotechnology startups?
CuResponse's latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's CuResponse Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CuResponse is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.